Abstract. Cyclin D1 and insulin-like growth factor 1 receptor (IGF-1R) are key regulators of cell proliferation that are overexpressed in most breast cancers. The purpose of the present study was to investigate the molecular mechanism by which hemin exerts its inhibitory effects on aggressive breast cancer cells. We found that hemin regulates cyclin D1 and IGF-1R proteins and insulin-like growth factor-1 gene expression through STAT5b in breast cancer cells. We confirmed that STAT5b, cyclin D1, and IGF-1R is up-regulated by hypoxia, and the increased STAT5b binds strongly to the STAT5-binding sites contained within the distal 5'-flanking region of IGF-1 gene in breast cancer cells. EMSA studies showed that STAT5 binding activity to the IGF-1 and cyclin D1 promoter was distinctly decreased by hemin in STAT5b-transfected COS-7 or MDA-MB 231 cells. IGF-1 gene expression was also decreased by hemin in mammary epithelial cells. STAT5b expression was inhibited in siRNA experiments and by hemin, leading to decreased levels of IGF-1. These results provide a basis for molecular targets in cancer treatment via the STAT5b/IGF-1 or /cyclin D1 pathway in solid tumor cells.
Introduction
Heme (ferroprotoporphyrin IX) is a prosthetic group found in a relatively large number of cellular hemoproteins (hemecontaining proteins) that carry out diverse biological functions. In its oxidized state, when it is known as hemin (ferriprotoporphrin IX), heme is bound less tightly to hemoglobin, and interacts more readily with alternative acceptor proteins and the lipid membranes of cells. Hemin (ferric chloride heme) is, as a natural agent, an essential growth promoter of early hematopoietic progenitors (BFU-Es, CFU-Es), and a potent inducer of globin gene activation. Hemin has therapeutic potential as a natural regulator of hematopoiesis, as well as an agent that protects hematopoietic cells from cytotoxic treatment (drugs, hypoxia, or other stimuli), for treatment of hematological and even neurodegenerative disorders (1) .
Insulin-like growth factors (IGFs), including IGF-I and IGF-II, are a family of polypeptide growth factors structurally related to proinsulin (2) . IGF-1 mediates many of the growthpromoting effects of growth hormones during post-natal life (3, 4) . Interest in the role of the IGF axis in growth control and carcinogenesis has increased because elevated serum IGF-I levels are associated with three of the most prevalent cancers in the United States: prostate cancer, colorectal cancer, and lung cancer (5, 6 ). In 1998, Physicians' Health Study researchers reported that men with high IGF-1 blood levels run a greater risk of prostate cancer. Similar results for breast cancer in premenopausal women in the Nurses' Health Study were released the same year, and a solid association in the case of colorectal cancer was reported in 1999 (7) . Cyclin D1 is amplified in about 15% of breast cancer cases. However, cyclin D1 is overexpressed at the mRNA and protein level in >50% of breast cancers, in the presence or absence of gene amplification. It is one of the most commonly overexpressed proteins in breast cancer. The D-type cyclins link the extracellular signals to the cell-cycle machinery and of the three D-type cyclins, it is cyclin D1 that is predominantly associated with human tumorigenesis (8) .
STATs (signal transducers and activators of transcription) may affect proliferation by regulating the expression of immediate-early genes, such as c-myc and c-fos, as well as cell cycle regulatory genes, such as the cyclins (9) . The Jak/STAT pathways are activated by various growth factors and cytokines. Binding of these cytokines to their receptors activates the Jak tyrosine kinases, followed by tyrosine phosphorylation of the receptors. This leads to activation and homo-or heterodimerization of the STAT5 transcription factors, translocation into the nucleus, and activation of target genes (10) . The products of the closely related (<90% identical) and chromosomally linked STAT5a and -5b genes are activated by a wide range of cytokines (11) . Despite the amino acid identity between STAT5a and -5b of approximately 95% and their redundant roles in regulating blood and cancer cell function, the two transcription factors also appear to have functional differences (12) . For example, STAT5b is selectively important for growth hormone signaling (13) , whereas STAT5a is particularly critical for prolactin-induced mammary gland differentiation (14, 15) . Earlier studies from our own laboratory have shown that STAT5b, but not STAT5a, may be a directional mediator of the IGF-1 and cyclin D1 gene expression produced by hypoxia in human HepG2 cells (16) and breast cancer cells (17) (18) (19) (20) , respectively. In similar results, recent evidence indicates that STAT5b, but not STAT5a, has a pro-proliferate role in breast, head and neck, and prostate cancers (17, 18, 21, 22) . Since STAT5b mediates breast cancer proliferation, identification of kinases that increase STAT5b activity is critical to identifying potential therapeutic targets (23) .
In 2005, a distal STAT5-binding DNA region was identified that may mediate GH regulation of IGF-1 gene expression (24) . GH stimulation of IGF-I gene expression is directly mediated by STAT5, so the cis-regulatory DNA regions involved may be the regions that contain STAT5-binding sites. A region within the rat IGF-I intron 2 has recently been shown to contain two STAT5-binding sites and to mediate GH-stimulated IGF-I gene expression in the liver of rats (25) , and to mediate hypoxia-stimulated IGF-1 gene expression in breast cancer cells (16) . A 700-bp DNA region 75 kb upstream of the human IGF-I exon 1 was found to contain two closely located STAT5-binding sites that were able to bind to STAT5 proteins, thus enabling the STAT5 activation of gene expression. Binding of STAT5 to this region increased gene expression from both heterologous and homologous promoters, and was associated with increased IGF-I mRNA expression.
Oxygen limitation is central in controlling neovascularization, glucose metabolism, survival, and tumor spread. Hypoxia initiates transcription of a number of gene products that help sustain the supply of O 2 to tissues and enhance cell survival during severe O 2 deprivation. Hypoxia is also a stressor that alters signal transduction and gene stability. In the cancer microenvironment, hypoxia plays a significant role in determining the phenotype and progression of the tumor (16) (17) (18) (19) (20) 26, 27) .
In this study, we proposed that hemin inhibits IGF-1 and cyclin D1 expression via STAT5b under hypoxic conditions in invasive and metastatic MDA-MB 231 breast cancer cells. To test this hypothesis, we investigated the effects of hemin on human MDA-MB 231 breast cancer cells, viability assay, inhibition of STAT5b, the binding of STAT5b to the STAT5-binding sites in the promoter of IGF-1 or cyclin D1 gene, the decrease of 700 bp IGF-I-pGL2 or cyclin D1 promoter activity, the decrease in expression of IGF-1 mRNA, and the reduction of IGF-1 mRNA or cyclin D1 and IGF-1R by STAT5b knockdown under hypoxic conditions. We found that hemin inhibits IGF-1 and cyclin D1 expression via STAT5b under hypoxic conditions in MDA-MB 231 breast cancer cells. Cell culture. MDA-MB 231, human breast cancer cells, were grown to confluency in L-15 medium containing 10% FBS and 100 U/ml penicillin. HC11, mouse mammary epithelial cells, were grown to confluency in RPMI-1640 medium containing 10% FBS, insulin (5 μg/ml), and EGF (10 ng/ml). COS-7, monkey kidney cells, and CHO, chinese hamster ovary cells, were cultured in DMEM containing 10% FBS, 2 mM glutamine, and 100 U/ml penicillin and streptomycin at 37˚C in 5% CO 2 . At the start of each experiment, the cells were resuspended in the medium at a density of 2.5x10 5 cells/ml. For hypoxic conditions, the cells were placed in airtight chambers (NuAire, Plymouth, MN, USA), which were flushed with a 5% carbon dioxide/95% nitrogen mixture until the oxygen concentration was 2%.
Materials and methods

Materials
Total cell lysis. MDA-MB 231 cells were treated with fac and hemin under normoxic/hypoxic conditions (2% O 2 ) for determined times. Cells were lysed on ice for 10 min in radioimmunoprecipitation assay (RIPA) lysis buffer containing protease and phosphatase inhibitors (50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 150 mM NaCl, 10 mM sodium phosphate, 10 mM sodium fluoride, 1 mM sodium orthovanadate, 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride, and 2 mg/ ml leupeptin, 4 mg/ml aprotinin, 1 mg/ml pepstatin). Cells were disrupted by aspiration through a 23-gauge needle, and centrifuged at 15,000 rpm for 10 min at 4˚C to remove cellular debris. Protein concentrations were measured using the Bradford method.
Western blot analyses. Whole cell extracts (WCE) from MDA-MB 231 cells and HC11 cells were prepared by lysing cells in RIPA buffer (50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 150 mM NaCl, and 1% Triton X-100) containing protease and phosphatase inhibitors (1 mM PMSF, 2 μg/ml leupeptin, 4 μg/ml aprotinin, and 1 μg/ml pepstatin). Equal amounts of protein obtained by total lysis were subjected to 8% SDS-PAGE and electrophoretically transferred onto a nitrocellulose membrane. Western blot analyses were performed as previously described.
Expression vectors and construction of plasmid vector.
The expression vectors for mouse STAT5b (pMX/STAT5b; kindly provided by Dr Koichi Ikuta, Kyoto University, Japan) were constructed as previously described. cDNA for STAT5b was inserted into the EcoRI and SalI sites of the pMX vector. Plasmid pGL2P is an enhancer-less plasmid containing SV40 promoter (Promega). 700 bp-pGL2P contains the 700-bp distal 5'-flanking region of IGF-I gene, identified as a STAT5-binding enhancer, compared with pGL2P (kindly provided by Dr Honglin Jiang, Virginia Polytechnic Institute and State University, USA). The insert from 700 bp-pGL2P was inserted into the pGL2-promoter vector at the SmaI and KpnI sites.
Electrophoretic mobility shift assay (EMSA)
. COS-7 cells into 35-mm culture dishes were transfected with STAT5b DNA constructs (1 μg) using the FuGene 6 according to the manufacturer's instructions. STAT5b DNA binding activity was detected using an electrophoretic mobility shift assay (EMSA), in which a labeled double-stranded DNA sequence was used as a DNA probe to bind active STAT5b protein in nuclear extracts. Double-stranded oligonucleotides corresponding to the STAT5b binding site 1 (5'-TAATTCTAAGA AACT-3') and site 2 (5'-TTTTTCTTAGAAGTA-3') in the distal 5'-flanking region of the human IGF-1 gene were end-labeled with [ 32 P] using T4 polynucleotide kinase and [Á-
32 P]ATP. EMSA were performed as previously described.
Cotransfection and luciferase assay. For reporter gene assays, CHO cells were transiently co-transfected with the plasmid pGL2P or 700 bp-pGL2P construct (24) and the STAT5b expression vector. Transfected cells were washed twice with ice-cold PBS, and 150 μl of lysis buffer was added to the wells. Lysates were then used directly to measure luciferase activity. For luciferase assays, 100 μl of cell lysates were mixed with 350 μl of assay buffer containing 25 mM glycylglycine, pH 7.8, 15 mM MgSO 4 , 4 mM EGTA, 5 mM ATP, and 1 mM DTT. The luciferase activity of each sample was determined by measuring luminescence for 10 sec on a Lumat LB 9507 luminometer (EG&G Berthold, Oak
Ridge, TN) after injection of 100 μl of 1 mM luciferine. The experiments were performed in triplicate, and similar results were obtained from at least three independent experiments.
RNA interference. The siRNA constructs for the STAT5b siRNA (pKD-STAT5b-v1) and negative control (pKDNegCon-v1) were purchased from Upstate (Lake Placid, NY). The 21-nucleotide siRNA target sequence was designed using a highly advanced search algorithm. The sequence has perfect complementarity to the STAT5b gene target, but minimal or no homology to other sequences within the genome. The siRNA target sequence was utilized to design the DNA oligonucleotides that were cloned into the pKD vector (Upstate, Lake Placid, NY). HC11 cells into 35-mm culture dishes were transfected with STAT5b siRNA (pKDSTAT5b-v1, 1 μg) or negative control (pKD-Negcon-v1, 1 μg) using the FuGene6 (Roche Applied Science) according to the manufacturer's instructions.
Real-time polymerase chain reaction. Total RNA from HC11 cells transfected with STAT5b siRNA or negative control was purified by an RNeasy mini kit (Qiagen). Isolated RNA samples were quantified by a spectrophotometric analysis at 260 nm. The cDNA synthesis and the probe used for the detection of IGF-1 and ß-actin from a TaqMan gene expression assay kit (Applied Biosystems Inc.). PCR was monitored in real-ime using the on ABI PRISM 7900 HT Real-time PCR System (Applied Biosystems Inc., Foster City, CA).
Data analysis and statistics.
The results of the experiments are expressed as mean ± SEM. Statistical analysis was done by t-tests or ANOVA-tests using the SAS program.
Results
Cytotoxicity of hemin in human breast cancer cells.
To determine the effect of hemin on cell survival, a human breast cancer cell line (MDA-MB 231) was exposed to various concentrations of hemin (10, 20, or 40 μM) for 6 h under hypoxic conditions. The number of hemin-treated cells in the logarithmic phase of growth was compared with that of control cells (hypoxia-treated cells). Cell growth was inhibited by~30% with 10 μM hemin and by ~50% with 20 μM hemin (Fig. 1) . Hemin treatment substantially decreased the viability of MDA-MB 231 cells in a dose-dependent manner. CA by FAC or hemin (Fig. 3A) . IGF-1 binding activity at the STAT5b DNA binding site-1 was markedly decreased in hemin-treated COS-7 or MDA-MB-231 cells. In particular, hemin completely blocked hypoxia-induced STAT5b DNA-binding activity in COS-7 cells transfected with STAT5b
CA and MDA-MB 231 cells under hypoxic conditions (Fig. 3A and B) whereas, the STAT5 DNA (cyclin D1)-binding activities were markedly decreased in FAC-treated COS-7 cells under normoxia and in hemintreated COS-7 cells under hypoxia (Fig. 3C ) (data not shown for binding site-2 of IGF-1).
The inhibition of 700 bp-IGF-I -pGL2 or cyclin D1 promoter activities by hemin under hypoxia. The effects of hemin on the transcriptional activation of IGF-1 was examined using a human IGF-1 promoter-luciferase construct, which contains sequences for STAT5 binding sites 1 and 2 in conjunction with a luciferase reporter. Since the 700-bp distal 5'-flanking region of the IGF-I gene containing the STAT5-binding site can mediate transactivation by STAT5, the 700-bp DNA region was inserted 5' to the SV40 promoter in the enhancerless pGL2P plasmid to generate plasmid 700 bp IGF-IpGL2P (24) . CHO cells were transiently co-transfected with the STAT5b construct and pGL2P or 700 bp IGF-I-pGL2P. They were incubated under normoxic or hypoxic conditions over 12 h. As shown in Fig. 4A , the relative luciferase activity of STAT5b/pGL2P under hypoxic conditions was increased over that at normoxic conditions. In particular, the relative luciferase activity (the reporter gene expression) from the STAT5b/700 bp IGF-I-pGL2P by hemin under hypoxic condition decreased compared with STAT5b/pGL2P or STAT5b/700 bp IGF-I-pGL2P by control or FAC under hypoxic conditions (p<0.01). As compared with the control, hemin decreased the relative luciferase activity of STAT5b/ 700 bp IGF-I-pGL2P by 70% under hypoxic conditions, suggesting that the STAT5b protein may be a critical mediator of the STAT5b/IGF-1 pathway by hypoxia, and hemin could be a strong candidate drug.
The effects of FAC or hemin on the transcriptional activation of cyclin D1 was examined using a human cyclin D1 promoter-luciferase construct, which contains a distal cyclin D1 promoter (GAS1) sequence upstream of a luciferase reporter. CHO cells were transiently co-transfected with the cyclin D1 (GAS1) construct and STAT5b/dn or STAT5b, then cultured in serum-free media with FAC or hemin treatment under normoxic or hypoxic conditions. As shown in Fig. 4B , the relative luciferase activities of the STAT5b/cyclin D1 promoter significantly decreased after 6 h of hemin treatment under hypoxic conditions (p<0.01), whereas the relative luciferase activities of the STAT5b/dn/cyclin D1 promoter were only slightly affected by FAC or hemin under normoxic or hypoxic conditions. As compared with the control, the relative luciferase activity of STAT5b/cyclin D1 (6 h) decreased 70% with hemin treatment under hypoxic conditions. These results suggest that the STAT5b protein may be a critical mediator of the STAT5b/cyclin D1 pathway by hemin under hypoxia.
The decrease in IGF-1 mRNA expression due to hemin. Hemin was examined for its effects on IGF-1 gene expression under normoxic and hypoxic conditions as follows. mRNA was isolated from HC11 cells, which were incubated under normoxic conditions and hypoxic conditions (2% O 2 ), and subjected to real-time PCR for IGF-1 gene amplification.
Real-time PCR was performed using an ABI 7900 HT real-time PCR system according to the TaqMan Gene Expression Assay method. The expression levels of IGF-1 gene were obtained by conducting the above procedure 3 times, and were normalized against the level of ß-actin mRNAs. The results are graphed in Fig. 5 , where asterisks show statistically significant decreases (>50%) in IGF-1 gene expression by hemin under hypoxic conditions as compared with a hypoxic control or FAC, as determined using an ANOVA test (p<0.05). However, they were unaffected under normoxic conditions.
Reduction of cyclin D1 and IGF-1R protein or IGF-1 mRNA expression by STAT5b knock-down.
An examination was made of the inhibition of a small interference RNA (si-STAT5b) against STAT5b, cyclin D1, and IGF-1R proteins or IGF-1 gene expression (STAT5b knock-down by si-STAT5b). In this regard, MDA-MB 231 cells were incubated with control or pKD-NegCon (mock) and interference RNA siSTAT5b (pKD-siSTAT5b) for 24 h in a normal atmosphere and a 2% O 2 atmosphere. After being harvested, the cells were subjected to immunoblotting against STAT5b, cyclin D1, IGF-1R and ß-actin to analyze the expression levels thereof (Fig. 6A) . Treatment of MDA-MB 231 cells with siRNASTAT5b resulted in efficient and specific inhibition of STAT5b transcripts. The siRNA-STAT5b showed cyclin D1 and IGF-1R expression under hypoxia in MDA-MB 231 cells that was significantly high compared with normoxia (Fig.  6A ). As seen in Fig. 6B , siRNA-STAT5b acted to decrease IGF-1 gene expression. Under hypoxic conditions, the HC11 cells transformed with pKD-siSTAT5b underwent a 70% decrease in IGF-1 mRNA level while the control was not affected at all. The decreased level of IGF-1 mRNA was also confirmed through real-time PCR. Thus, IGF-1 is a target gene of hypoxia signal transduction, and regulation of IGF-1 mRNA level is likely to be the result of hypoxia activation of STAT5b.
Discussion
We have reported that STAT5b mediates and regulates the transactivation of cyclin D1 by hypoxia stimulation in breast cancer cells, suggesting a novel biological role for STAT5b in the regulation of hypoxia-signaling pathways (17) (18) (19) , and we recently reported that hypoxia activates IGF-1 expression through STAT5b in human HepG2 cells (16) , and enhancement of hypoxia-induced apoptosis of human breast cancer cells via STAT5b by momilactone B (20). STAT5 proteins activate the expression of the cyclin D1 gene through the recognition of a conserved element in the promoter (28, 29) . As one of the target genes activated by the STAT cascade, cyclin D1 is probably an important mediator of the STAT-dependent growth of hematopoietic cells. However, the exact role of this protein in this signaling pathway is yet to be determined. It has been postulated that the activated form of STAT5 due to hypoxia may contribute to one level of control by modulation of the transcriptional activity of the cyclin D1 promoter. However, differences in transcriptional activities of STAT5a and -5b induced by hypoxia have been shown. It is known that ligand-dependent and -independent signal transduction pathways may differentially regulate STAT5a and -5b nuclear translocation, and therefore have the potential to differentially regulate STAT5-dependent gene expression (30) .
Novel functions of STAT5b, a new target of breast tumor kinase/protein tyrosine kinase 6 have been reported (23) , and another function of STAT5b in breast cancer cell migration was demonstrated (31) . The authors suggested that STAT5b not only functions in the initiation of tumorigenesis, through its pro-proliferative and pro-survival signaling, but may also promote tumor progression by mediating migration, using two aggressive, highly migratory breast cancer cell lines (MDA-MB 231 and BT-549).
Insulin-like growth factor 1 (IGF-1) appears to play a crucial role in cell division, proliferation, growth, and metastasis of most solid cancers, such as breast cancer and prostate cancer. During angiogenesis, a hypoxic condition is created around solid cancer cells, stimulating oncogenes and oncoproteins of the cells. Thus, solid cancer cells become more malignant and undergo cell division, proliferation, growth, and metastasis, for which IGF is responsible. IGF-1 plays an important role in tumorigenesis and tumor progression in a variety of tumors and is a potent mitogen in cancer cells (32, 33) . However, the mechanism of regulating IGF-1 expression by cytokines, growth hormone, or hypoxia in humans has been difficult to study, in part because of the lack of an appropriate cell model (13) . Based on recent findings that GH regulation of IGF-I gene expression in the liver depends on STAT5b (34, 35) and STAT5a (36, 37) , Wang and Jiang (24) screened the entire human IGF-I gene as well as an extensive 5-flanking region for sequences that can function as STAT5-binding enhancers.
Insulin-like growth factor 1 receptor (IGF-1R) and cyclin D1 are the key regulators of cell proliferation that are overexpressed in most breast cancers (38) . In particular, levels of IGF-1 has been associated with breast cancer risk among premenopausal women (39) . As a recent trend in breast cancer among younger women in the United States, the annual percentage change in the incidence of invasive breast cancers decreased modestly among older women, but increased among younger (<40 years) white women. But the mechanisms that influence the incidence of breast cancer in premenopausal women are less well understood (7) .
There is a needed to prove that IGF-I has a role in human malignancy. Again, using estrogen and ER· as a model, two areas need to be further explored. First, a method to block IGF action must be shown to be effective as a cancer therapy. For estrogen action, ovariectomy in pre-menopausal women demonstrated that lowering circulating estrogen levels had a therapeutic benefit in patients with advanced cancer. The development of tamoxifen unequivocally showed that ER· is a key target in breast cancer, and eventually led to the observation that administration of tamoxifen reduced breast cancer risk in healthy women. Second, it needs to be proven that raising levels of IGF-I enhances cancer risk. The effect of concomitant increases in IGFBP-3 also needs to be evaluated (40) .
Hemin (iron-protoporphyrin IX), the Fe 3+ oxidation product of heme, is a natural agent that promotes growth of hematopoietic cells and induces erythroid differentiation in human leukemias, like K-562 and HEL cells. Hemin acts as a feedback inhibitor to ALA synthase. Hemin also inhibits transport of ALA synthase from the cytosol (its site of synthesis) into the mitochondria (its site of action) as well as repressing synthesis of the enzyme. Hemin has been shown to inhibit apoptosis in human monocytes (41) despite caspase 3 upregulation. These findings taken together suggest that heme is a determinant of life and death in renal tubular epithelial (42) and other cell types like hematopoietic and liver cells. Another interesting observation about hemin that has attracted worldwide attention from a clinical perspective is its unique ability to selectively inhibit the transcription of embryonic and fetal, but not of adult, globin gene in K-562 cells (43, 44) .
Some investigators suggested that hemin can be therapeutically valuable agent in the treatment of ß˚-thalassemia because it selectively promotes HbF (·2Á2) synthesis. Administration of hemin arginate in thalassemic patients was found to elevate hemoglobin content by 3-fold without causing any serious adverse reactions (45) . In addition to thalassemia, hemin arginate has been used as a drug of choice to treat patients suffering from acute porphyries with severe neurological manifestations. Also, hemin is a potentially cytotoxic compound; several studies have demonstrated the ability of hemin to initiate lipid peroxidation (46) and to cause the degradation of protein (47) and DNA (48) . It has also been shown that exposure to hemin is capable of enhancing the sensitivity of endothelial cells to oxidative injury (49) . Additionally, hemin is both a potent inducer of and substrate for the inducible isoform of heme oxygenase (HO-1) (50). While Tsiftsoglou et al (1) have observed that hemin protected human normal and leukemic hematopoietic cells from cytotoxicity induced by anthracyclines, in particular adriamycin. However, it has not been made clear how hemin protects cells from cytotoxicity induced by antineoplastic agents, although recently it has been shown that hemin activates expression of HO-1 (HSP32) in order to protect cells against oxidative stress (51, 52) . Hemin has also been shown to protect several other cell types (hepatocytes, gastric cancer cells, renal tubular epithelial cells) from oxidative stress induced by H 2 O 2 , cisplatin, tumor necrosis factor-· (TNF-·), and even tetrachloride (CCl 4 ), via activation of the HO-1 gene (50, (53) (54) (55) (56) (57) .
In this study, we hypothesized that hemin could suppress the hypoxia-induced cyclin D1 and IGF-1 expression of metastatic breast cancer cells. To test this hypothesis, we generated stable cyclin D1-and IGF-1R-expressing cells of the highly invasive/metastatic MDA-MB 231 breast cancer cells and mammary epithelial cells (HC11), and tested their levels under hypoxia compared with their control counterparts. Hemin substantially decreased the viability of MDA-MB 231 cells in a dose-dependent manner at 20 μM of hemin, as an IC 50 (Fig. 1) . We also found that proteins of STAT5b, cyclin D1, and IGF-1R were more overexpressed under hypoxic conditions than under normoxic conditions ( Fig. 2A) , and hemin suppressed hypoxia-induced increases in STAT5b, cyclin D1 and IGF-1R protein levels (Fig. 2B) . The STAT5b DNA-binding activity to IGF-1 or cyclin D1 promoters were markedly decreased in hemin-treated COS-7 or MDA-MB 231 cells under hypoxia (Fig. 3) , and the IGF-1 or cyclin D1 promoter activities were significantly decreased by hemin under hypoxia of MDA-MB 231 cells (Fig. 4) . Moreover, IGF-1 mRNA expression by hemin decreased by 40% under hypoxic conditions (Fig. 5) . Finally, we found that hypoxia-stimulated cyclin D1 and IGF-1R or IGF-1 expression requires STAT5b (Fig. 6) .
This finding applies to the IGF-I pathway and cancer. Several studies have shown that IGF-I activation of its receptor stimulates ER· function. In ER· expressing breast cancer cells, IGF-I and estradiol act synergistically to enhance growth (58) (59) (60) . Multiple pathways may be responsible for estrogen/IGF-I synergy, but enhancement of ER· transcriptional activity by IGF-I signaling is one likely mechanism (61, 62) . Thus, IGF-I has a role in human malignancy. It seems likely that within a few years, the relationship of IGF-I to human cancer will be established. These findings are valuable in understanding the role of hemin-induced inhibition of cyclin D1 and IGF-1 expression under hypoxic condition of ER·-negative breast cancer cells, as a novel strategy for preventing ER-negative breast cancer. In addition, hemin can be a therapeutically valuable agent, exerting its activities via the JAK2/STAT5b pathway, thus lowering the incidence of more aggressive ER-negative breast cancers, which are associated with a poorer prognosis compared to ER-positive cancer.
